NASDAQ · ANAB
Healthcare · Biotechnology
$54.68
Up+$0.57 (+1.05%)
Updated Sep 16, 2026, 6:39 AM
SID Score
4.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
ANAB closed at $54.68 after 20 trading sessions, down 7.31% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $54.28 | $55.32 | $53.22 | $54.68 | 351.77K |
| Sep 14, 2026 | $54.58 | $55.70 | $54.00 | $54.11 | 436.88K |
| Sep 11, 2026 | $55.43 | $56.315 | $53.75 | $53.87 | 336.19K |
| Sep 10, 2026 | $55.43 | $56.43 | $54.31 | $55.16 | 300.15K |
| Sep 9, 2026 | $55.59 | $57.89 | $55.25 | $55.70 | 295.68K |
| Sep 8, 2026 | $55.48 | $58.165 | $54.79 | $56.60 | 1.04M |
| Sep 4, 2026 | $56.84 | $58.77 | $56.10 | $56.80 | 1.06M |
| Sep 3, 2026 | $56.33 | $57.77 | $55.00 | $57.46 | 366.85K |
| Sep 2, 2026 | $56.13 | $57.90 | $54.66 | $55.84 | 421.73K |
| Sep 1, 2026 | $56.82 | $58.09 | $54.84 | $55.28 | 773.86K |
| Aug 31, 2026 | $55.83 | $57.22 | $55.00 | $57.03 | 332.17K |
| Aug 28, 2026 | $57.24 | $57.24 | $55.375 | $56.28 | 358.57K |
| Aug 27, 2026 | $58.03 | $58.43 | $57.101 | $57.29 | 533.74K |
| Aug 26, 2026 | $58.27 | $58.86 | $57.365 | $58.00 | 210.37K |
| Aug 25, 2026 | $58.09 | $58.99 | $56.805 | $58.37 | 341.84K |
| Aug 24, 2026 | $56.96 | $59.065 | $55.565 | $58.44 | 627.05K |
| Aug 21, 2026 | $57.23 | $58.78 | $56.62 | $57.74 | 318.37K |
| Aug 20, 2026 | $58.52 | $59.69 | $56.33 | $56.69 | 389.39K |
| Aug 19, 2026 | $60.31 | $60.31 | $58.43 | $59.26 | 258.75K |
| Aug 18, 2026 | $58.90 | $60.02 | $58.16 | $58.99 | 260.45K |
The latest Smart Investors Daily articles mentioning ANAB.
ANAB research
Company profile and research snapshot.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 25, 2026 | TD Cowen | Buy | — |
| Aug 24, 2026 | HC Wainwright & Co. | Buy | — |
| May 13, 2026 | UBS | Buy | — |
| May 13, 2026 | Barclays | Overweight | — |
| May 4, 2026 | Piper Sandler | Overweight | — |
No generated briefing is available yet.
Yahoo · Sep 9, 2026
Alphyn Capital Management, an investment management firm, released its second-quarter 2026 investor letter. The letter can be downloaded here. The fund’s Master Account returned 0.6% net in the quarter compared to 15.2% for the S&P500. As of June 30, 2026, the top ten positions comprised approximately 72% of the portfolio, and the portfolio held approximately […]
Yahoo · Sep 1, 2026
SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced that Chris Murphy, chief financial officer, is scheduled to present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, Sept. 15, 2026. The presentation is scheduled to begin at 3:30pm ET. A live webcast of the presentation will be available on the investor section of the
Benzinga · Aug 25, 2026
TD Cowen analyst Joseph Thome maintains AnaptysBio (NASDAQ:ANAB) with a Buy and lowers the price target from $75 to $70.
Benzinga · Aug 24, 2026
HC Wainwright & Co. analyst Joseph Pantginis reiterates AnaptysBio (NASDAQ:ANAB) with a Buy and maintains $95 price target.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ANAB.
